Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities:
Net loss	$ (136,937)	$ (138,595)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5,077	3,002
Expensed in-process research and development	2,679
Premium amortization and discount accretion on investment securities	787	1,790
Stock-based compensation	40,695	35,087
Non-cash lease expense	3,806	3,305
Amortization of debt discount and issuance cost	320	312
Foreign exchange adjustment	265	(281)
Loss on investments		46
Amortization of other assets		143
Non-cash interest expense	48	4
Changes in operating assets and liabilities:
Accounts receivable	(2,400)	(45,788)
Inventory	(5,277)	1,860
Prepaid expenses and other assets	2,338	(6,366)
Accounts payable	5,762	(7,557)
Accrued compensation	14,993	(8,545)
Operating lease liabilities	(2,177)	(2,765)
Other accrued liabilities	(18,181)	21,336
Deferred revenue	7,312	5,735
Cash used in operating activities	(80,890)	(137,277)
Investing activities:
Purchases of investments		(24,977)
Proceeds from sale of investments		166,895
Proceeds from maturity of investments	27,250	81,000
Purchases of property and equipment, net	(11,598)	(15,885)
Cash provided by investing activities	15,652	207,033
Financing activities:
Proceeds from exercise of stock options	2,301	4,156
Cash provided by financing activities	2,301	4,156
Net change in cash, cash equivalents and restricted cash	(62,937)	73,912
Cash, cash equivalents and restricted cash, beginning of period	466,091	84,614
Cash, cash equivalents and restricted cash, end of period	403,154	158,526
Supplemental disclosure of cash flow information:
Cash paid for interest	1,124	159
Non-cash investing and financing activities:
Purchases of property and equipment in accounts payable and accruals	1,613	$ 2,096
Issuance of common stock for IPR&D acquisition	14,435
Issuance of common stock for bonus	$ 19,771